HC Wainwright Reaffirms “Buy” Rating for MiNK Therapeutics (NASDAQ:INKT)

MiNK Therapeutics (NASDAQ:INKT)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $35.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 336.41% from the stock’s current price.

MiNK Therapeutics Stock Down 5.9 %

MiNK Therapeutics stock traded down $0.50 during midday trading on Tuesday, hitting $8.02. 10,271 shares of the stock were exchanged, compared to its average volume of 15,557. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $19.00. The business’s 50-day moving average price is $8.93 and its 200-day moving average price is $7.74. The stock has a market capitalization of $31.78 million, a price-to-earnings ratio of -2.06 and a beta of 0.16.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Tuesday, March 18th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.12). On average, sell-side analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.